Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants
催化抗氧化剂对病理性新血管形成的长期抑制
基本信息
- 批准号:8607958
- 负责人:
- 金额:$ 53.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-02-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAge related macular degenerationAnimalsAntioxidantsBasic ScienceBlindnessBloodBlood VesselsCellsCeriumChronicClinical ResearchConfocal MicroscopyCoupledDataDevelopmentDiabetic RetinopathyDiseaseEconomic BurdenEffectivenessElectroretinographyEnzymesEpithelialExtravasationEye diseasesGene ExpressionGene ProteinsGenesGoalsHealthHypoxiaInflammationIntercellular JunctionsKnockout MiceKnowledgeLesionLiquid substanceLongevityLongitudinal StudiesMacular degenerationMass Spectrum AnalysisMusNuclearOptical Coherence TomographyOutcomeOxidative StressPathologicPathologic NeovascularizationPathologyPatientsPhasePhotoreceptorsPlasmaProductionPublishingQuality of lifeReactive Oxygen SpeciesResearchRetinaRetinalRetinal DegenerationRetinal DiseasesRetinal EdemasRetinal NeovascularizationRetinal PigmentsStructure of retinal pigment epitheliumSulforaphaneTestingTherapeuticTherapeutic AgentsTherapeutic UsesThickTimeVLDL receptorVascular Endothelial Growth FactorsVisionWestern BlottingWorkangiogenesisbasecerium oxide nanoparticlecombinatorialcostimprovedin vivoinherited retinal degenerationneovascularneovascularizationparticlepreventproliferative diabetic retinopathyprotein structureregenerativeresearch studytherapeutic target
项目摘要
DESCRIPTION (provided by applicant): In some forms of Diabetic Retinopathy (DR) and Macular Degeneration (AMD), blindness results from the pathologic development of new blood vessels which are incomplete, weak and porous. The progression of these neovascular diseases is thought to occur through the production of toxic molecules, Reactive Oxygen Species (ROS). There are no long term successful therapies for such diseases which have devastating effects on patients and cost the USA over $50 billion/yr. Our long term goal is to develop a therapeutic treatment to protect the health and function of retinal cells and thereby prolong vision and improve the quality of life for patients with DR or AMD. Because the excessive rise in ROS occurs "upstream" of most other retinal pathologies, it represents a common node which can be targeted by antioxidants and other molecules which increase the expression of "Phase II" antioxidant enzymes. Our published and preliminary data show that cerium oxide nanoparticles, which catalytically destroy ROS, can prevent development of pathologic choroidal and retinal neovascular lesions and cause the regression of existing pathologic neovessels in the Very Low Density Lipoprotein Receptor null retina by modulating the expression of many retinal genes including Vascular Endothelial Growth Factor (VEGF). Our central hypothesis is that cerium oxide nanoparticles, because of their catalytic antioxidant activity and long term retention in the retina, will continuously scavenge ROS and inhibit pathologic neovascularization over prolonged times -up to 12 months. Specific aim 1 will determine duration of nanoceria in the retina and the extent to which they retain activity against neovascularization. Inductively coupled plasma mass spectrometry will quantitate cerium at the parts per billion levels. Fundoscopy, electroretinography and optical coherence tomography will be used for longitudinal studies on the same animal to evaluate neovascularization, retinal function and thickness of the outer nuclear layer. Nanoceria effects on specific genes involved in oxidative stress, inflammation and neovascularization will be analyzed using confocal microscopy, Western blots and PCR arrays. Specific Aim 2 will demonstrate that nanoceria provide protection to the retina by reducing the effects of oxidative stress on photoreceptors and Retinal Pigment Epithelial (RPE) cells. Gene activity, proteins and structures indicative of photoreceptor- and/or RPE- oxidative stress will be evaluated. Specific Aim 3 will test the hypothesis that the combinatorial use of nanoceria and sulforaphane, an inducer of Phase II antioxidant enzymes, will result in an additive or synergistic effects in the Vldlr retina. Expected outcomes - the work proposed is expected to demonstrate the longevity, potency and mechanisms by which nanoceria inhibit pathologic neovascularization in the retina. The results are expected to have an important positive impact because the demonstration of the long term effectiveness of the nanoceria will most likely support their therapeutic use and changes in activity of identified genes should provide additional targets important for treating DR, AMD and other diseases which involve oxidative stress.
描述(由申请人提供):在某些形式的糖尿病视网膜病变(DR)和黄斑变性(AMD)中,失明是由于新血管的病理发展造成的,这些血管是不完整的、脆弱的和多孔的。这些新生血管疾病的进展被认为是通过产生毒性分子活性氧(ROS)而发生的。对于这些疾病没有长期成功的疗法,这些疾病对患者具有破坏性影响,并且每年花费美国超过500亿美元。我们的长期目标是开发一种治疗方法,以保护视网膜细胞的健康和功能,从而延长DR或AMD患者的视力并改善其生活质量。由于ROS的过度升高发生在大多数其他视网膜病变的“上游”,因此它代表了可以被抗氧化剂和增加“II期”抗氧化酶表达的其他分子靶向的共同节点。我们发表的和初步的数据表明,氧化铈纳米颗粒,催化破坏活性氧,可以防止病理性脉络膜和视网膜新生血管病变的发展,并导致现有的病理性新生血管在非常低密度脂蛋白受体无效的视网膜通过调节许多视网膜基因,包括血管内皮生长因子(VEGF)的表达消退。我们的中心假设是,氧化铈纳米颗粒,因为它们的催化抗氧化活性和长期保留在视网膜中,将持续清除ROS和抑制病理性新血管形成的时间延长-长达12个月。具体目标1将确定纳米氧化铈在视网膜中的持续时间以及它们保留抗新血管形成活性的程度。电感耦合等离子体质谱法将定量铈在十亿分之几的水平。眼底镜检查、视网膜电图和光学相干断层扫描将用于同一动物的纵向研究,以评价新生血管形成、视网膜功能和外核层厚度。纳米氧化铈对参与氧化应激、炎症和新生血管形成的特定基因的影响将使用共聚焦显微镜、蛋白质印迹和PCR阵列进行分析。具体目标2将证明纳米氧化铈通过减少氧化应激对光感受器和视网膜色素上皮(RPE)细胞的影响来保护视网膜。将评价指示光感受器-和/或RPE-氧化应激的基因活性、蛋白质和结构。具体目标3将检验以下假设:纳米氧化铈和萝卜硫素(II相抗氧化酶的诱导剂)的组合使用将在Vldlr视网膜中产生累加或协同效应。预期成果-所提出的工作预计将证明纳米氧化铈抑制视网膜中病理性新生血管形成的寿命、效力和机制。预期结果将具有重要的积极影响,因为纳米氧化铈的长期有效性的证明将最有可能支持其治疗用途,并且所鉴定的基因的活性的变化将提供对于治疗DR、AMD和涉及氧化应激的其他疾病重要的额外靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES Francis MCGINNIS其他文献
JAMES Francis MCGINNIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES Francis MCGINNIS', 18)}}的其他基金
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants
催化抗氧化剂对病理性新血管形成的长期抑制
- 批准号:
8222309 - 财政年份:2012
- 资助金额:
$ 53.69万 - 项目类别:
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants
催化抗氧化剂对病理性新血管形成的长期抑制
- 批准号:
8415878 - 财政年份:2012
- 资助金额:
$ 53.69万 - 项目类别:
Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants
催化抗氧化剂对病理性新血管形成的长期抑制
- 批准号:
8798665 - 财政年份:2012
- 资助金额:
$ 53.69万 - 项目类别:
Cellular Imaging and Morphometric Analysis Core
细胞成像和形态测量分析核心
- 批准号:
10011811 - 财政年份:2011
- 资助金额:
$ 53.69万 - 项目类别:
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE
COBRE:OUHSC:图像采集
- 批准号:
8360403 - 财政年份:2011
- 资助金额:
$ 53.69万 - 项目类别:
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE
COBRE:OUHSC:图像采集
- 批准号:
8168347 - 财政年份:2010
- 资助金额:
$ 53.69万 - 项目类别:
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth Nanoparticles
通过治疗性稀土纳米颗粒预防遗传性视网膜疾病
- 批准号:
7583201 - 财政年份:2009
- 资助金额:
$ 53.69万 - 项目类别:
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE
COBRE:OUHSC:图像采集
- 批准号:
7959974 - 财政年份:2009
- 资助金额:
$ 53.69万 - 项目类别:
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth Nanoparticles
通过治疗性稀土纳米颗粒预防遗传性视网膜疾病
- 批准号:
7895588 - 财政年份:2009
- 资助金额:
$ 53.69万 - 项目类别:
COBRE:OUHSC: IMAGE ACQUISITION & PRODUCTION CORE
COBRE:OUHSC:图像采集
- 批准号:
7720537 - 财政年份:2008
- 资助金额:
$ 53.69万 - 项目类别:
相似海外基金
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
- 批准号:
10102692 - 财政年份:2024
- 资助金额:
$ 53.69万 - 项目类别:
EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
- 批准号:
10639785 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
- 批准号:
23K09052 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
- 批准号:
10642988 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
- 批准号:
10635325 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
- 批准号:
10584110 - 财政年份:2023
- 资助金额:
$ 53.69万 - 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
- 批准号:
22H03243 - 财政年份:2022
- 资助金额:
$ 53.69万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
- 批准号:
10433610 - 财政年份:2022
- 资助金额:
$ 53.69万 - 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
- 批准号:
10504138 - 财政年份:2022
- 资助金额:
$ 53.69万 - 项目类别: